{"id":"hydronidone-capsules","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Osteoporosis"},{"rate":null,"effect":"Immunosuppression/increased infection risk"},{"rate":null,"effect":"Adrenal suppression"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a synthetic corticosteroid, hydronidone exerts anti-inflammatory effects through glucocorticoid receptor activation, leading to decreased production of inflammatory cytokines and immune cell activation. It is used in capsule formulation for systemic delivery to treat inflammatory and autoimmune conditions.","oneSentence":"Hydronidone is a corticosteroid that reduces inflammation and suppresses immune responses by binding to glucocorticoid receptors.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:48:05.995Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Inflammatory and autoimmune disorders (specific indications in phase 3 development unknown)"}]},"trialDetails":[{"nctId":"NCT07417553","phase":"PHASE2","title":"A Study of Hydronidone Capsules in Patients With Chronic Hepatitis B Virus-Related Liver Fibrosis","status":"NOT_YET_RECRUITING","sponsor":"Beijing Continent Pharmaceutical Co, Ltd.","startDate":"2026-03-15","conditions":"Chronic Hepatitis B-related Liver Fibrosis","enrollment":150},{"nctId":"NCT07412236","phase":"PHASE3","title":"A Phase IIIc Clinical Study to Evaluate the Long-term Treatment of Hydronidone Capsules for Liver Fibrosis in Patients With Chronic Hepatitis B.","status":"NOT_YET_RECRUITING","sponsor":"Beijing Continent Pharmaceutical Co, Ltd.","startDate":"2026-01-30","conditions":"Liver Fibrosis, Liver Fibrosis in Chronic Hepatitis B","enrollment":1208},{"nctId":"NCT07394309","phase":"PHASE1","title":"Study of Hydroxynidone Capsules in Patients With Hepatic Impairment and Matched Healthy Controls","status":"NOT_YET_RECRUITING","sponsor":"Beijing Continent Pharmaceutical Co, Ltd.","startDate":"2026-02-15","conditions":"Liver Fibrosis","enrollment":30},{"nctId":"NCT07364448","phase":"PHASE2","title":"A Study to Evaluate the Safety of Hydronidone Capsules in Patients With Liver Fibrosis","status":"NOT_YET_RECRUITING","sponsor":"Beijing Continent Pharmaceutical Co, Ltd.","startDate":"2026-01-30","conditions":"Chronic Hepatitis B With Hepatic Fibrosis","enrollment":200},{"nctId":"NCT07343778","phase":"PHASE3","title":"A Clinical Trial Evaluating the Safety of Hydronidone Capsules in Patients With Hepatic Fibrosis and Liver Cirrhosis","status":"NOT_YET_RECRUITING","sponsor":"Beijing Continent Pharmaceutical Co, Ltd.","startDate":"2026-01-20","conditions":"Chronic Hepatitis B With Hepatic Fibrosis","enrollment":300},{"nctId":"NCT07262333","phase":"PHASE1","title":"A Trial of Hydroxynidone Capsules in Single-dose Administration for Patients With Renal Insufficiency","status":"RECRUITING","sponsor":"Beijing Continent Pharmaceutical Co, Ltd.","startDate":"2025-12-25","conditions":"Renal Insufficiency Chronic","enrollment":56},{"nctId":"NCT07295873","phase":"PHASE1","title":"Drug-Drug Interaction Study Between Hydronidone and Entecavir, Tenofovir Disoproxil Fumarate, Tenofovir Alafenamide, and Tenofovir Amibufenamide","status":"NOT_YET_RECRUITING","sponsor":"Beijing Continent Pharmaceutical Co, Ltd.","startDate":"2025-12-30","conditions":"Chronic Hepatitis B Liver Fibrosis, DDI (Drug-Drug Interaction)","enrollment":64},{"nctId":"NCT07263152","phase":"PHASE1","title":"QTc Assessment in a Single-Dose Study of Hydronidone Capsules","status":"NOT_YET_RECRUITING","sponsor":"Beijing Continent Pharmaceutical Co, Ltd.","startDate":"2025-12-01","conditions":"Hepatic Fibrosis","enrollment":48},{"nctId":"NCT07262346","phase":"PHASE1","title":"The Phase Ⅰd Clinical Trial of Hydronidone Capsules","status":"NOT_YET_RECRUITING","sponsor":"Beijing Continent Pharmaceutical Co, Ltd.","startDate":"2025-12-05","conditions":"Liver Fibrosis","enrollment":138},{"nctId":"NCT05905172","phase":"PHASE3","title":"Hydronidone Capsules in Long-term Treatment in Patients With Chronic Viral Hepatitis B Liver Fibrosis","status":"RECRUITING","sponsor":"Beijing Continent Pharmaceutical Co, Ltd.","startDate":"2023-08-12","conditions":"Liver Fibrosis","enrollment":248},{"nctId":"NCT05115942","phase":"PHASE3","title":"Hydronidone for the Treatment of Liver Fibrosis Associated with Chronic Viral Hepatitis B Phase 3 Trial.","status":"COMPLETED","sponsor":"Beijing Continent Pharmaceutical Co, Ltd.","startDate":"2021-12-30","conditions":"Liver Fibrosis","enrollment":248},{"nctId":"NCT02499562","phase":"PHASE2","title":"A Phase II Clinical Trial of Hydronidone Capsules(F351) in Patients With Liver Fibrosis Induced by HBV Chronic Hepatitis","status":"COMPLETED","sponsor":"Shanghai Genomics, Inc.","startDate":"2015-06-25","conditions":"Hepatitis B, Chronic","enrollment":168},{"nctId":"NCT04162821","phase":"PHASE1","title":"Study on Pharmacokinetics of Hydronidone","status":"COMPLETED","sponsor":"Beijing Continent Pharmaceutical Co, Ltd.","startDate":"2019-10-30","conditions":"Pharmacokinetics of Hydronidone","enrollment":48},{"nctId":"NCT04123769","phase":"PHASE1","title":"Study on PK of Hydronidone in Patients and Special Population","status":"COMPLETED","sponsor":"Beijing Continent Pharmaceutical Co, Ltd.","startDate":"2019-09-03","conditions":"Hepatitis b & Liver Dysfunction","enrollment":8},{"nctId":"NCT04125056","phase":"NA","title":"Study on Hydronidone Capsule BE","status":"COMPLETED","sponsor":"Beijing Continent Pharmaceutical Co, Ltd.","startDate":"2019-01-16","conditions":"Healthy","enrollment":40},{"nctId":"NCT04124081","phase":"PHASE1","title":"Pharmacokinetic Interactions Between Hydronidone and Entecavir Capsules in Healthy Chinese Subjects","status":"COMPLETED","sponsor":"Beijing Continent Pharmaceutical Co, Ltd.","startDate":"2019-05-15","conditions":"Hydronidone","enrollment":12}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["F351"],"phase":"phase_3","status":"active","brandName":"Hydronidone capsules","genericName":"Hydronidone capsules","companyName":"Beijing Continent Pharmaceutical Co, Ltd.","companyId":"beijing-continent-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Hydronidone is a corticosteroid that reduces inflammation and suppresses immune responses by binding to glucocorticoid receptors. Used for Inflammatory and autoimmune disorders (specific indications in phase 3 development unknown).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}